Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study

被引:75
作者
DelBello, Melissa P. [1 ]
Goldman, Robert [2 ]
Phillips, Debra [3 ]
Deng, Ling [3 ]
Cucchiaro, Josephine [3 ]
Loebel, Antony [3 ]
机构
[1] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[2] Sunov Pharmaceut, Marlborough, MA USA
[3] Sunov Pharmaceut, Ft Lee, NJ USA
关键词
bipolar depression; clinical trial; lurasidone; QUALITY-OF-LIFE; RATING-SCALE; OPEN-LABEL; PSYCHOMETRIC PROPERTIES; CARDIOVASCULAR-DISEASE; SCIENTIFIC STATEMENT; DISORDER; SCHIZOPHRENIA; QUETIAPINE; VALIDITY;
D O I
10.1016/j.jaac.2017.10.006
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
Objective: To evaluate the efficacy and safety of lurasidone in children and adolescents with bipolar depression. Method: Patients 10 to 17 years old with a DSM-5 diagnosis of bipolar I depression were randomized to 6 weeks of double-blind treatment with flexible doses of lurasidone 20 to 80 mg/day. The primary endpoint was change from baseline to week 6 in the Children's Depression Rating Scale-Revised (CDRS-R) total score, evaluated by a mixed-model repeated-measures analysis. Results: A total of 347 patients were randomized and received at least 1 dose of lurasidone (n = 175; mean age 14.2 years; mean dose 33.6 mg/day) or placebo (n = 172; mean age 14.3 years). At week 6, treatment with lurasidone was associated with statistically significant improvement compared with placebo in CDRS-R total score (-21.0 versus-15.3; p < .0001; effect size 0.45). Lurasidone also was associated with statistically significant improvement in the Clinical Global Impression Bipolar Severity depression score (key secondary measure) and in measures of anxiety, quality of life, and global functioning. Study completion rates were 92.0% in the lurasidone group and 89.7% in the placebo group; discontinuation rates due to adverse events were the same for the 2 groups (1.7%). The 2 most common adverse events on lurasidone were nausea and somnolence. Treatment with lurasidone was associated with few effects on weight and metabolic parameters. Conclusion: In this placebo-controlled study, mono therapy with lurasidone, in the dose range of 20 to 80 mg/day, significantly decreased depressive symptoms in children and adolescents with bipolar depression. Lurasidone was well tolerated, with minimal effects on weight and metabolic parameters.
引用
收藏
页码:1015 / 1025
页数:11
相关论文
共 54 条
[1]   Phenomenology of children and adolescents with bipolar spectrum disorders [J].
Axelson, David ;
Birmaher, Boris ;
Strober, Michael ;
Gill, Mary Kay ;
Valeri, Sylvia ;
Chiappetta, Laurel ;
Ryan, Neal ;
Leonard, Henrietta ;
Hunt, Jeffrey ;
Iyengar, Satish ;
Bridge, Jeffrey ;
Keller, Martin .
ARCHIVES OF GENERAL PSYCHIATRY, 2006, 63 (10) :1139-1148
[2]  
BIRD HR, 1987, ARCH GEN PSYCHIAT, V44, P821
[3]   Four-Year Longitudinal Course of Children and Adolescents With Bipolar Spectrum Disorders: The Course and Outcome of Bipolar Youth (COBY) Study [J].
Birmaher, Boris ;
Axelson, David ;
Goldstein, Benjamin ;
Strober, Michael ;
Gill, Mary Kay ;
Hunt, Jeffrey ;
Houck, Patricia ;
Ha, Wonho ;
Iyengar, Satish ;
Kim, Eunice ;
Yen, Shirley ;
Hower, Heather ;
Esposito-Smythers, Christianne ;
Goldstein, Tina ;
Ryan, Neal ;
Keller, Martin .
AMERICAN JOURNAL OF PSYCHIATRY, 2009, 166 (07) :795-804
[4]  
Carter MJ, 2014, THER RECREAT J, V48, P275
[5]   Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype [J].
Cates, Lindsay N. ;
Roberts, Amanda J. ;
Huitron-Resendiz, Salvador ;
Hedlund, Peter B. .
NEUROPHARMACOLOGY, 2013, 70 :211-217
[6]   Adult bipolar disorder is continuous with pediatric bipolar disorder [J].
Chang, Kiki .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2007, 52 (07) :418-425
[7]   Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic [J].
Citrome, L. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (02) :189-210
[8]   Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study [J].
Citrome, Leslie ;
Weiden, Peter J. ;
McEvoy, Joseph P. ;
Correll, Christoph U. ;
Cucchiaro, Josephine ;
Hsu, Jay ;
Loebel, Antony .
CNS SPECTRUMS, 2014, 19 (04) :330-339
[9]   Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study [J].
Correll, Christoph U. ;
Cucchiaro, Josephine ;
Silva, Robert ;
Hsu, Jay ;
Pikalov, Andrei ;
Loebel, Antony .
CNS SPECTRUMS, 2016, 21 (05) :393-402
[10]   Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents [J].
Correll, Christoph U. ;
Manu, Peter ;
Olshanskiy, Vladimir ;
Napolitano, Barbara ;
Kane, John M. ;
Malhotra, Anil K. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (16) :1765-1773